CSL
CSL is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people.
We focus and demonstrate global leadership in three distinct areas—rare and serious diseases; influenza vaccines; and iron deficiency and nephrology.
CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas.
As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. CSL Seqirus utilizes egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries.
King of Prussia, PA 19406
of innovation! From lifesaving
treatments to groundbreaking
vaccines, we’re rewriting the future.
CSL Behring
A global leader in biotherapies for rare and serious conditions like bleeding disorders and immunodeficiencies.
CSL Seqirus
Focused on developing essential vaccines to protect people of all ages from infectious diseases.
CSL Vifor
Providing innovative treatments for patients with chronic kidney disease and iron deficiency.
CSL Plasma
One of the world’s largest plasma collection networks, ensuring a critical source of lifesaving therapies.
